EVLV

Evolv is a real revenue-generating business with a differentiated, AI-grounded product (Evolv Express + eXpedite) addressing a tangible end-market — schools, healthcare, sports, live entertainment — where, as the 10-K Risk Factors put it, venues are 'moving toward a more frictionless security screening experience.' The numbers back the narrative: revenue grew from $23.4M in FY2021 to $145.9M in FY2025 (+40.5% YoY), gross margin is a healthy 51.6%, and net loss narrowed from -$108M in FY2023 to -$33.1M in FY2025. Critically, operating cash flow flipped meaningfully positive to $18.7M (+160.5% YoY), signaling the subscription-driven model is starting to self-fund.

The MD&A flags a real near-term wrinkle: the Columbia Tech distributor licensing arrangement expired December 31, 2025, and 'license revenue from this agreement is expected to reduce to zero over time, replaced by increased product revenue.' Management frames this as long-term gross-profit accretive over the duration of contracts, but it introduces an optical revenue-mix headwind in 2026 that the market may misread. Pair that with -33.2% operating margin, a -$388M accumulated deficit, and -27.7% ROE, and this is still a company burning GAAP capital to grow.